November 5, 2018

Enhanced Special Authorization Process Update

On January 1, 2017, we implemented an enhanced special authorization (ESA) process which changed the way we manage special authorization requests for medications used to treat certain chronic health conditions. As of November 1, 2018, as part of our latest benefits update, we are expanding the ESA process to include two additional health conditions—ankylosing spondylitis and psoriatic arthritis.

ARTA Retiree Benefits Plan members who currently have special authorization approval for a medication used to treat ankylosing spondylitis or psoriatic arthritis will not be impacted unless they require a special authorization renewal after November 1 or they are prescribed a new medication. Renewals and medication changes will be required to go through the ESA process, as well as new medication requests for plan members who haven’t previously requested special authorization approval.

Plan members who require a special authorization renewal for medications used to treat ankylosing spondylitis or psoriatic arthritis after November 1, will be contacted by the ARTA Retiree Benefits Plan to inform them of the new process.

For more information on the ESA process, visit the Enhanced Special Authorization section of the Claim Forms page. You can also contact an ARTA benefit plan coordinator with any questions at arta@asebp.ca or toll-free at 1-855-444-ARTA (2782).